The study of of imetelstat in combination with ruxolitinib in patients with myelofibrosis

The company Geron Corporation is commencing recruitment for the clinical trial of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis.

The condition is Myelofibrosis.

The trial officially began on the May 4, 2022 and is planned to complete on December 5, 2026.

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in combination with ruxolitinib in participants with MF in Part 2.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05371964.

Clinical Research News

Upcoming Clinical Trials